Oncolytics Biotech, Inc. (ONCY)
0.372
-0.04
(-9.62%)
USD |
NASDAQ |
Nov 12, 16:00
0.3619
-0.01
(-2.72%)
After-Hours: 06:58
Oncolytics Biotech Enterprise Value : 42.70M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 42.70M |
| November 11, 2026 | 47.63M |
| November 10, 2026 | 43.92M |
| November 09, 2026 | 47.15M |
| November 06, 2026 | 51.10M |
| November 05, 2026 | 52.27M |
| November 04, 2026 | 49.28M |
| November 03, 2026 | 44.94M |
| November 02, 2026 | 46.19M |
| October 30, 2026 | 49.35M |
| October 29, 2026 | 49.64M |
| October 28, 2026 | 51.37M |
| October 27, 2026 | 53.95M |
| October 26, 2026 | 55.31M |
| October 23, 2026 | 58.94M |
| October 22, 2026 | 58.68M |
| October 21, 2026 | 60.07M |
| October 20, 2026 | 58.48M |
| October 19, 2026 | 58.19M |
| October 16, 2026 | 58.41M |
| October 15, 2026 | 64.58M |
| October 14, 2026 | 63.41M |
| October 13, 2026 | 57.41M |
| October 12, 2026 | 55.32M |
| October 09, 2026 | 65.76M |
| Date | Value |
|---|---|
| October 08, 2026 | 64.19M |
| October 07, 2026 | 70.59M |
| October 06, 2026 | 70.87M |
| October 05, 2026 | 70.73M |
| October 02, 2026 | 74.98M |
| October 01, 2026 | 76.25M |
| September 30, 2026 | 79.62M |
| September 29, 2026 | 80.40M |
| September 28, 2026 | 78.97M |
| September 25, 2026 | 81.50M |
| September 24, 2026 | 80.99M |
| September 23, 2026 | 80.65M |
| September 22, 2026 | 85.24M |
| September 21, 2026 | 91.84M |
| September 18, 2026 | 92.30M |
| September 17, 2026 | 92.30M |
| September 16, 2026 | 92.15M |
| September 15, 2026 | 93.55M |
| September 14, 2026 | 97.63M |
| September 11, 2026 | 89.25M |
| September 10, 2026 | 92.55M |
| September 09, 2026 | 95.42M |
| September 08, 2026 | 96.67M |
| September 04, 2026 | 101.43M |
| September 03, 2026 | 103.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Revolution Medicines, Inc. | 35.70B |
| Arrowhead Pharmaceuticals, Inc. | 6.429B |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 1.891B |
| Anixa Biosciences, Inc. | 77.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.442M |
| Total Expenses (Quarterly) | 9.442M |
| EPS Diluted (Quarterly) | -0.0788 |
| Earnings Yield | -73.25% |
| Normalized Earnings Yield | -73.36 |